Gainers

• American Well (NYSE:AMWL) stock moved upwards by 31.2% to $5.68 during Friday's regular session. The market value of their outstanding shares is at $68.4 million. The company's, Q4 earnings came out yesterday.
• Phio Pharma (NASDAQ:PHIO) stock increased by 28.68% to $1.57. The market value of their outstanding shares is at $13.1 million.
• Immunic (NASDAQ:IMUX) shares rose 27.57% to $1.11. The company's market cap stands at $104.6 million.
• Cypherpunk Technologies (NASDAQ:CYPH) stock rose 21.12% to $0.73. The company's market cap stands at $33.9 million.
• Oncolytics Biotech (NASDAQ:ONCY) shares increased by 18.59% to $0.99. The market value of their outstanding shares is at $89.8 million.
• CASI Pharmaceuticals (NASDAQ:CASI) shares rose 17.59% to $0.88. The market value of their outstanding shares is at $11.5 million.

Losers

• Intensity Therapeutics (NASDAQ:INTS) shares fell 26.3% to $0.27 during Friday's regular session. The market value of their outstanding shares is at $22.2 million.
• Geovax Labs (NASDAQ:GOVX) shares fell 23.85% to $1.76. The market value of their outstanding shares is at $4.0 million.
• Upstream Bio (NASDAQ:UPB) shares fell 21.22% to $10.09. The market value of their outstanding shares is at $691.6 million.
• OKYO Pharma (NASDAQ:OKYO) stock decreased by 20.51% to $1.73. The market value of their outstanding shares is at $88.0 million.
• Sensus Healthcare (NASDAQ:SRTS) stock decreased by 18.18% to $3.81. The market value of their outstanding shares is at $76.3 million. As per the press release, Q4 earnings came out yesterday.
• Polaryx Therapeutics (NASDAQ:PLYX) stock decreased by 16.1% to $2.45. The company's market cap stands at $138.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.